View:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 3, 1996
ENZON, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12957 22-237286
- -------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
Item 5. Other Events
Enzon, Inc. (the "Enzon" or the "Company") announced at the
1996 Annual Meeting of Shareholders that under Enzon's agreement with the Green
Cross Corporation, a Japanese pharmaceutical company, for recombinant Human
Serum Albumin, (rHSA) is currently in Phase III clinical trials in Japan as a
blood volume expander. The market in Japan for rHSA is approximately $400
million. While the agreement entitles Enzon to a customary pharmaceutical
royalty on product sales, Green Cross has requested reduction of the royalty.
Enzon is considering all its options under the agreement.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: December 19, 1996
ENZON, INC.
(Registrant)
By: /S/KENNETH J.ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer